Clinical Trial Update: MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

View source ↗

Summary

A clinical trial from the University of Rome Tor Vergata is evaluating MR-proADM as an early biomarker for delayed graft function and acute rejection in kidney …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Liver Transplantation

Snippet

Sponsor: University of Rome Tor Vergata | Conditions: Kidney Transplant; Complications, Liver Transplant; Complications | Status: RECRUITING